Advertisement

Related Videos

Mark J. Ratain, MD: The Justification for a Randomized Trial of Low-Dose Ibrutinib

Mark Sculpher, PhD: How Do We Assess the Value of Cancer Drug Optimization?

Javid J. Moslehi, MD, on Cardiovascular and Thrombotic Considerations of Kinase Inhibitors: The Case of BTK Inhibitors

S. Vincent Rajkumar, MD, on Cost-Effective Treatment of Multiple Myeloma

David T. Rubin, MD, on Biosimilars for Inflammatory Bowel Disease

Advertisement

Advertisement




Mar
10
Today In Oncology
Activity Observed with Novel KRAS Inhibitor in Pancreatic Cancer
AI-Backed Liquid Biopsies Identify Liver Diseases
Peter WT Pisters Honored With Top Award From Society of Surgical Oncology
TACE With Camrelizumab and Rivoceranib in Unresectable Hepatocellular Carcinoma
Clinical Trials May Misrepresent True Thromboembolic Risks From Cancer Drugs
View More 
Advertisement
© 2026 HSP News Service, L.L.C.
Conexiant Oncology Logo